Literature DB >> 16051923

Human umbilical cord blood-derived cells differentiate into hepatocyte-like cells in the Fas-mediated liver injury model.

Kazunobu Nonome1, Xiao-Kang Li, Terumi Takahara, Yusuke Kitazawa, Naoko Funeshima, Yutaka Yata, Feng Xue, Masami Kanayama, Eiji Shinno, Chieko Kuwae, Shigeru Saito, Akiharu Watanabe, Toshiro Sugiyama.   

Abstract

Human umbilical cord blood (HUCB) contains stem/progenitor cells, which can differentiate into a variety of cell types. In this study, we investigated whether HUCB cells differentiate into hepatocytes in vitro and in vivo. We also examined whether CD34 could be the selection marker of stem cells for hepatocytes. HUCB cells were obtained from normal full-term deliveries, and CD34(+/-) cells were further separated. For in vitro study, HUCB cells were cultured for 4 wk, and expressions of liver-specific genes were examined. For the in vivo study, nonobese diabetic/severe combined immunodeficient mice were subjected to liver injury by a Fas ligand-carried adenoviral vector or only radiated. Mice were treated simultaneously with or without cell transplantation of HUCB, CD34(+), or CD34(-) cells. After 4 wk, human-specific gene/protein expression was examined. In the in vitro study, human liver-specific genes were positive after 7 days of culture. The immunofluorescent study showed positive staining of alpha-fetoprotein, cytokeratin 19, and albumin in round-shaped cells. In the in vivo study, immunohistochemical analysis showed human albumin-positive, hepatocyte-specific antigen-positive cells in mouse livers of the Fas ligand/transplantation group. Fluorescence in situ hybridization analysis using the human Y chromosome also showed positive signals. However, no difference between transplanted cell types was detected. In contrast, immunopositive cells were not detected in the irradiated/transplantation group. The RT-PCR result also showed human hepatocyte-specific gene expressions only in the Fas ligand/transplantation group. HUCB cells differentiated into hepatocyte-like cells in the mouse liver, and liver injury was essential during this process. The differences between CD34(+) and CD34(-) cells were not observed in human hepatocyte-specific expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051923     DOI: 10.1152/ajpgi.00049.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  6 in total

1.  New concepts in liver regeneration.

Authors:  Kimberly J Riehle; Yock Y Dan; Jean S Campbell; Nelson Fausto
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

2.  Reversal of Hepatic Fibrosis by Human CD34(+) Stem/Progenitor Cell Transplantation in Rats.

Authors:  M T Abdel Aziz; Mf El Asmar; S Mostafa; H Salama; H M Atta; S Mahfouz; N K Roshdy; L A Rashed; D Sabry; N Hasan; M Mahmoud; D Elderwy
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

3.  Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo.

Authors:  Christopher S Gondi; Krishna Kumar Veeravalli; Bharathi Gorantla; Dzung H Dinh; Dan Fassett; Jeffrey D Klopfenstein; Meena Gujrati; Jasti S Rao
Journal:  Neuro Oncol       Date:  2010-01-22       Impact factor: 12.300

4.  Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens.

Authors:  Nicolas Brezillon; Dina Kremsdorf; Mary C Weiss
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

5.  Phenotypic changes of human cells in human-rat liver during partial hepatectomy-induced regeneration.

Authors:  Yan Sun; Dong Xiao; Hong-An Li; Jin-Fang Jiang; Qing Li; Ruo-Shuang Zhang; Xi-Gu Chen
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

Review 6.  The role of stem cells in physiology, pathophysiology, and therapy of the liver.

Authors:  Amar Deep Sharma; Tobias Cantz; Michael P Manns; Michael Ott
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 6.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.